Before stabilized IPTW, ticagrelor group patients were younger; more frequently presented with ST-elevation myocardial infarction (STEMI); received PCI or coronary stenting; and were treated with glycoprotein IIb/IIIa inhibitors, angiotensin-converting enzyme inhibitors, beta-blockers, and statins during hospitalization, whereas clopidogrel group patients were older and had higher rates of non-STEMI (NSTEMI), peripheral artery disease, and previous MI and bleeding events. This evidence concerns the gene ACE and peripheral arterial disease.